vimarsana.com

Latest Breaking News On - Mei pharma inc - Page 1 : vimarsana.com

MEI Pharma (MEIP) Reports Initial Data from Study of ME-344 in Combination with Bevacizumab

MEI Pharma (MEIP) Reports Initial Data from Study of ME-344 in Combination with Bevacizumab
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

MEI Pharma (MEIP) Board Aligns on Strategy to Advance Voruciclib and ME-344

MEI Pharma (MEIP) Board Aligns on Strategy to Advance Voruciclib and ME-344
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

MEI Pharma (MEIP) Reports Update from Clinical Study of Voruciclib in Combination with Venetoclax

MEI Pharma (MEIP) Reports Update from Clinical Study of Voruciclib in Combination with Venetoclax
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

MEI Pharma (NASDAQ:MEIP) Stock Price Crosses Below 200-Day Moving Average of $6 02

MEI Pharma, Inc. (NASDAQ:MEIP – Get Free Report) crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $6.02 and traded as low as $4.25. MEI Pharma shares last traded at $4.26, with a volume of 17,436 shares trading hands. Analysts Set New Price Targets A […]

Investment Analysts Weekly Ratings Changes for MEI Pharma (MEIP)

Several analysts have recently updated their ratings and price targets for MEI Pharma (NASDAQ: MEIP): 2/14/2024 – MEI Pharma had its price target lowered by analysts at Stifel Nicolaus from $8.00 to $7.00. They now have a “hold” rating on the stock. 2/13/2024 – MEI Pharma was downgraded by analysts at StockNews.com from a “buy” […]

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.